• Login
NORVANREPORTS.COM |  Business News, Insurance, Taxation, Oil & Gas, Maritime News, Ghana, Africa, World
  • Home
  • News
    • General
    • Political
  • Economy
  • Business
    • Agribusiness
    • Aviation
    • Banking & Finance
    • Energy
    • Insurance
    • Manufacturing
    • Markets
    • Maritime
    • Real Estate
    • Tourism
    • Transport
  • Technology
    • Telecom
    • Cyber-security
    • Cryptocurrency
    • Tech-guide
    • Social Media
  • Features
    • Interviews
    • Opinions
  • Reports
    • Banking/Finance
    • Insurance
    • Budgets
    • GDP
    • Inflation
    • Central Bank
    • Sec/Gse
  • Lifestyle
    • Sports
    • Entertainment
    • Travel
    • Environment
    • Weather
  • NRTV
    • Audio
    • Video
No Result
View All Result
No Result
View All Result
NORVANREPORTS.COM |  Business News, Insurance, Taxation, Oil & Gas, Maritime News, Ghana, Africa, World
No Result
View All Result
Home Business

Ghana, Rwanda and Senegal partner BioNTech to produce COVID-19 vaccines in Africa

3 years ago
in Business, Editor's pick, Environment, highlights, Home, home-news, latest News, Lifestyle
3 min read
0 0
0
88
VIEWS
Share on FacebookShare on TwitterShare on Linkedin

Ghana, Rwanda and Senegal partner BioNTech to produce COVID-19 vaccines in Africa

Ghana, Rwanda and Senegal are partnering with the German biotechnology company BioNTech SE to fill, finish and package BioNTech mRNA vaccines in Africa, as a first step in establishing a chain of domestic vaccine production which will help to improve vaccine supply in Africa.

The news was announced at a high-level meeting in Marburg, Germany, on Wednesday 16 February 2022, where President Akufo-Addo, together with Presidents Macky Sall of Senegal and Paul Kagame of Rwanda, witnessed the presentation of a BioNtech modular production facility solution for the production of mRNA vaccines in Africa.

The event was also attended Ursula von der Leyen, president of the European Commission, and Tedros Adhanom Ghebreyesus, director general of the World Health Organization.

Together with BioNTech’s co-founders Professors Uğur Şahin (who is also the firm’s chief executive officer) and Özlem Türeci (also the chief medical officer) and Dr Sierk Poetting (BioNTech chief operating officer), they discussed jointly the infrastructural, regulatory and technological requirements to establish an end-to-end manufacturing network for mRNA-based vaccines in Africa.

BioNTech SE has introduced this approach to establish scalable vaccine production by delivering turnkey mRNA manufacturing facilities based on a container solution. At a high-level meeting at BioNTech’s manufacturing facility in Marburg, and at the invitation of the kENUP Foundation, the company presented the container solution named “BioNTainer” to key partners for its efforts in Africa.

The “BioNTainer” modular production facility will consist of one drug substance and one drug product module, each built of six ISO-sized containers. These are clean rooms that BioNTech equips with state-of-the-art, semi-automated manufacturing solutions.

RelatedPosts

Chamber of Agribusiness Calls for Sector-Wide Price Cuts and Urgent Government Support to Curb Food Crisis

The Perils of Market Interventionism: When Political Pressures Threatens Ghana’s Economic Gains – The Way Forward

GAB Projects Drop in Lending Rates Starting August 6 Following BoG’s 300bps Policy Rate Cut

Each module requires 800 square metres of space and offers an estimated capacity of several hundred million doses of mRNA-based vaccines, depending on the specific vaccine.

Read: SIC records 12.5% gain in share price to emerge sole gainer on local bourse

Public-private partnership

The BioNTainer will be equipped to manufacture a range of mRNA-based approved or authorised vaccines, targeted to the needs of people in African Union member states, such as BioNTech’s COVID-19 vaccine, and its malaria and tuberculosis vaccines, if these are developed successfully and approved.

The first BioNTainer is expected to be shipped to the African Union in mid-2022. BioNTech expects to ship BioNTainers to Rwanda and Senegal in close alignment with the respective countries and the African Union. BioNTech will be responsible for the delivery and set-up of the modules, while local officials and governments will ensure the needed infrastructure.

Ghana will support the manufacturing with fill-and-finish capacities.

In co-operation with WHO, the Africa Centres for Disease Control and Prevention/African Medicines Agency, and the European Union, BioNTech is supporting, identifying and setting up the necessary regulatory framework.

BioNTech will initially staff, own and operate the facilities to support the safe and rapid initiation of the production of mRNA-based vaccine doses. In the longer term, the company plans to transfer manufacturing capacities and the knowhow to local partners to enable sustainable production of mRNA vaccines in Africa.

Vaccines manufactured in these facilities are expected to be dedicated to domestic use and export to other member states of the African Union at a not-for-profit price.

Pan-African project

Speaking at the launch event, President Akufo-Addo said the meeting heralds an important step in end-to-end vaccine manufacturing in Africa.

“This pan-African project fits very well in to Ghana’s roadmap for vaccine development and manufacturing, developed by the Vaccine Manufacturing Committee, which I constituted nearly a year ago,” he said.

The president added, “We are willing to work together with our counterparts in Rwanda and Senegal to fill, finish and package BioNTech mRNA vaccines, as a first step in the chain of domestic vaccine production.”

He told the gathering that Ghana’s Food and Drugs Authority (FDA), the principal Ghanaian regulatory agency, which is currently at WHO Maturity Level 3, being upgraded to Maturity Level 4, will be readily available to work closely with regulatory bodies from the two partner countries to enhance the regulatory capacities for domestic vaccine development and manufacturing in Africa.

Moreover, with Ghana’s growing pharmaceutical industry, which already has broad footprints in West Africa, President Akufo-Addo said that, backed by the nation’s industrious research institutions, strong political will and commitment, fuelled by lessons learned from the COVID-19 pandemic, he is of the utmost belief that Ghana is prepared for this project.

“We have gleaned a lot from this pandemic, and we are determined to enhance our ability to handle more efficiently any future outbreaks, including building domestic capacity for vaccine production. We are ready to contribute and to be part of the manufacturing of mRNA COVID-19, malaria and TB vaccines from drug substance through drug product to fill, finish and package. Ghana is raring to go,” he said.

Source: presidency.gov.gh
Via: norvanreports
Tags: BioNTech mRNA vaccines in AfricaCOVID-19 pandemicghanaRwanda and Senegal partner BioNTech to produce COVID-19 vaccines in Africa
No Result
View All Result

Highlights

Local Bourse Rallies Strongly as GSE-CI Hits Near 7,000 Mark

Treasury Exceeds Auction Target of GHS 3.86 Billion Amid Tightening Yields

BoG Raises GHS 15.38 Billion via 56-Day Bills to Reinforce Tight Monetary Policy Stance

Passage of Competition Law Key to Tackling DSTV’s Market Dominance – CUTS International

Why Are Interest Rates Still High? The MPR vs Market Rates Debate

Climate Change Is Making Africa’s Debt Burden Worse – New Debt Contracts Could Help

Trending

Agribusiness

Chamber of Agribusiness Calls for Sector-Wide Price Cuts and Urgent Government Support to Curb Food Crisis

August 4, 2025

Chamber of Agribusiness Calls for Sector-Wide Price Cuts and Urgent Government Support to Curb Food Crisis The...

The Perils of Market Interventionism: When Political Pressures Threatens Ghana’s Economic Gains – The Way Forward

August 4, 2025

GAB Projects Drop in Lending Rates Starting August 6 Following BoG’s 300bps Policy Rate Cut

August 4, 2025

Local Bourse Rallies Strongly as GSE-CI Hits Near 7,000 Mark

August 4, 2025

Treasury Exceeds Auction Target of GHS 3.86 Billion Amid Tightening Yields

August 4, 2025

Who we are?

NORVANREPORTS.COM |  Business News, Insurance, Taxation, Oil & Gas, Maritime News, Ghana, Africa, World

NorvanReports is a unique data, business, and financial portal aimed at providing accurate, impartial reporting of business news on Ghana, Africa, and around the world from a truly independent reporting and analysis point of view.

© 2020 Norvanreports – credible news platform.
L: Hse #4 3rd Okle Link, Baatsonaa – Accra-Ghana T:+233-(0)26 451 1013 E: news@norvanreports.com info@norvanreports.com
All rights reserved we display professionalism at all stages of publications

No Result
View All Result
  • Home
  • Business
    • Agribusiness
    • Aviation
    • Energy
    • Insurance
    • Manufacturing
    • Real Estate
    • Maritime
    • Tourism
    • Transport
    • Banking & Finance
    • Trade
    • Markets
  • Economy
  • Reports
  • Technology
    • Cryptocurrency
    • Cyber-security
    • Social Media
    • Tech-guide
    • Telecom
  • Features
    • Interviews
    • Opinions
  • Lifestyle
    • Entertainment
    • Sports
    • Travel
    • Environment
    • Weather
  • NRTV
    • Audio
    • Video

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
NORVANREPORTS.COM | Business News, Insurance, Taxation, Oil & Gas, Maritime News, Ghana, Africa, World
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.